Skip to main content
Erschienen in:

07.11.2024 | Originalie

Neuroprotektive und -regenerative Medikation nach schwerem Schädel-Hirn-Trauma

Sinnvolle Ergänzung der Intensivbehandlung?

verfasst von: Prim. Univ.-Prof. Dr. Helmut Trimmel, Ivan Grgac, Günther Herzer, Christian Matula

Erschienen in: Anästhesie Nachrichten | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ursächlich für ein schweres Schädel-Hirn-Trauma (sSHT) sind zum überwiegenden Teil Verkehrsunfälle bzw. Stürze. Neben der unmittelbaren Verletzung des Gehirns aggravieren sekundäre Prozesse die Schädigung oft beträchtlich. Der vorliegende Artikel beschreibt Ursachen und mögliche medikamentöse Ansätze zur Reduktion bzw. Behandlung dieses Sekundärschadens. Es wird dabei auf Medikamente Augenmerk gelegt, die in dieser Indikation zugelassen, ubiquitär verfügbar sind sowie als sicher und nebenwirkungsarm gelten.
Literatur
1.
Zurück zum Zitat Wang KK, Yang Z, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18:165–80.PubMedPubMedCentralCrossRef Wang KK, Yang Z, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18:165–80.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Jochems D, van Rein E, Nijboer T, et al. Incidence, causes and consequences of moderate and severe traumatic brain injury as determined by Abbreviated Injury Score in the Netherlands. Sci Rep. 2021;11:19985.PubMedPubMedCentralCrossRef Jochems D, van Rein E, Nijboer T, et al. Incidence, causes and consequences of moderate and severe traumatic brain injury as determined by Abbreviated Injury Score in the Netherlands. Sci Rep. 2021;11:19985.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Lorenz LS, Doonan M. Value and cost savings from access to multi-disciplinary rehabilitation services after severe acquired brain injury. Front Public Health. 2021;9:753447.PubMedPubMedCentralCrossRef Lorenz LS, Doonan M. Value and cost savings from access to multi-disciplinary rehabilitation services after severe acquired brain injury. Front Public Health. 2021;9:753447.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Fu TS, Jing R, McFaull SR, Cusimano MD. Health & economic burden of traumatic brain injury in the emergency department. Can J Neurol Sci J Can Des Sci Neurol. 2016;43:238–47.CrossRef Fu TS, Jing R, McFaull SR, Cusimano MD. Health & economic burden of traumatic brain injury in the emergency department. Can J Neurol Sci J Can Des Sci Neurol. 2016;43:238–47.CrossRef
5.
Zurück zum Zitat Secades JJ. Role of citicoline in the management of traumatic brain injury. Pharm. 2021;14:410. Secades JJ. Role of citicoline in the management of traumatic brain injury. Pharm. 2021;14:410.
6.
Zurück zum Zitat Vaccari JPR, Dietrich WD, Keane RW. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metabolism. 2013;34:369–75.CrossRef Vaccari JPR, Dietrich WD, Keane RW. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metabolism. 2013;34:369–75.CrossRef
7.
Zurück zum Zitat Jia Y, Wang G, Guo Z, et al. Niche Cells Crosstalk In Neuroinflammation After Traumatic Brain Injury. Int J Biol Sci. 2021;17:368–78.PubMedPubMedCentralCrossRef Jia Y, Wang G, Guo Z, et al. Niche Cells Crosstalk In Neuroinflammation After Traumatic Brain Injury. Int J Biol Sci. 2021;17:368–78.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Hall ED, Wang JA, Hill RL, et al. Newer pharmacological approaches for antioxidant neuroprotection in traumatic brain injury. Neuropharmacology. 2019;145:247–58.PubMedCrossRef Hall ED, Wang JA, Hill RL, et al. Newer pharmacological approaches for antioxidant neuroprotection in traumatic brain injury. Neuropharmacology. 2019;145:247–58.PubMedCrossRef
10.
Zurück zum Zitat Kabadi SV, Faden AI. Neuroprotective strategies for traumatic brain injury: improving clinical translation. Int J Mol Sci. 2014;15:1216–36.PubMedPubMedCentralCrossRef Kabadi SV, Faden AI. Neuroprotective strategies for traumatic brain injury: improving clinical translation. Int J Mol Sci. 2014;15:1216–36.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Rosenfeld JV, Maas AI, Gruen RL, et al. Early management of severe traumatic brain injury. Lancet. 2012;380:1088–98.PubMedCrossRef Rosenfeld JV, Maas AI, Gruen RL, et al. Early management of severe traumatic brain injury. Lancet. 2012;380:1088–98.PubMedCrossRef
12.
Zurück zum Zitat Ciryam P, Gerzanich V, Simard JM. Interleukin‑6 in traumatic brain injury: a janus-faced player in damage and repair. J Neurotrauma. 2023;. Ciryam P, Gerzanich V, Simard JM. Interleukin‑6 in traumatic brain injury: a janus-faced player in damage and repair. J Neurotrauma. 2023;.
13.
Zurück zum Zitat Collins-Praino LE, Corrigan F. Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury? Brain Behav Immun. 2017;60:369–82.PubMedCrossRef Collins-Praino LE, Corrigan F. Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury? Brain Behav Immun. 2017;60:369–82.PubMedCrossRef
14.
Zurück zum Zitat Shohami E, Biegon A. Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury. CNS Neurol Disord Drug Targets. 2014;13:567–73.PubMedCrossRef Shohami E, Biegon A. Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury. CNS Neurol Disord Drug Targets. 2014;13:567–73.PubMedCrossRef
15.
Zurück zum Zitat Taş YÇ, Solaroğlu İ, Gürsoy-Özdemir Y. Spreading depolarization waves in neurological diseases: a short review about its pathophysiology and clinical relevance. Curr Neuropharmacol. 2019;17:151–64.PubMedPubMedCentralCrossRef Taş YÇ, Solaroğlu İ, Gürsoy-Özdemir Y. Spreading depolarization waves in neurological diseases: a short review about its pathophysiology and clinical relevance. Curr Neuropharmacol. 2019;17:151–64.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Soldozy S, Sharifi KA, Liu L, et al. Cortical Spreading Depression in the Setting of Traumatic Brain Injury. World Neurosurg. 2020;134:50–7.PubMedCrossRef Soldozy S, Sharifi KA, Liu L, et al. Cortical Spreading Depression in the Setting of Traumatic Brain Injury. World Neurosurg. 2020;134:50–7.PubMedCrossRef
17.
Zurück zum Zitat Levi-Montalcini R. Growth control of nerve cells by a protein factor and its antiserum. Science. 1964;143:105–10.PubMedCrossRef Levi-Montalcini R. Growth control of nerve cells by a protein factor and its antiserum. Science. 1964;143:105–10.PubMedCrossRef
18.
Zurück zum Zitat Levi-Montalcini R. Recent studies on the NGF-target cells interaction. Differentiation. 1979;13:51–3.PubMedCrossRef Levi-Montalcini R. Recent studies on the NGF-target cells interaction. Differentiation. 1979;13:51–3.PubMedCrossRef
19.
Zurück zum Zitat Singhal NS, Sun C‑H, Lee EM, Ma DK. Resilience to injury: a new approach to neuroprotection? Neurotherapeutics. 2020;17:457–74.PubMedPubMedCentralCrossRef Singhal NS, Sun C‑H, Lee EM, Ma DK. Resilience to injury: a new approach to neuroprotection? Neurotherapeutics. 2020;17:457–74.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of Cerebrolysin. Medicinal Res Reve. 2023;. Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of Cerebrolysin. Medicinal Res Reve. 2023;.
21.
Zurück zum Zitat Carney N, Totten AM, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2016;1. Carney N, Totten AM, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2016;1.
22.
Zurück zum Zitat Hawryluk GWJ, Aguilera S, Cooper DJ, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intens Care Med. 2019;45:1783–94.CrossRef Hawryluk GWJ, Aguilera S, Cooper DJ, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intens Care Med. 2019;45:1783–94.CrossRef
23.
Zurück zum Zitat Trimmel H, Herzer G, Schöchl H, Voelckel WG. Intensive care treatment of traumatic brain injury in multiple trauma patients : decision making for complex pathophysiology. Der Unfallchirurg. 2017;120:739–44.PubMedCrossRef Trimmel H, Herzer G, Schöchl H, Voelckel WG. Intensive care treatment of traumatic brain injury in multiple trauma patients : decision making for complex pathophysiology. Der Unfallchirurg. 2017;120:739–44.PubMedCrossRef
24.
Zurück zum Zitat Marehbian J, Muehlschlegel S, Hwang DY, et al. Medical Management of the Severe Traumatic Brain Injury Patient. Neurocrit Care. 2017;27:430–46.PubMedPubMedCentralCrossRef Marehbian J, Muehlschlegel S, Hwang DY, et al. Medical Management of the Severe Traumatic Brain Injury Patient. Neurocrit Care. 2017;27:430–46.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Foundation BT. Surgeons AA of N, Carney NA, et al. Guidelines for the management of severe traumatic brain injury. Introduction. J Neurotrauma. 2007;24(Suppl 1):S1–2. Foundation BT. Surgeons AA of N, Carney NA, et al. Guidelines for the management of severe traumatic brain injury. Introduction. J Neurotrauma. 2007;24(Suppl 1):S1–2.
27.
Zurück zum Zitat Sparshott M. Früh- und Neugeborene pflegen. Stress- und schmerzreduzierende und entwicklungsfördernde Pflege. Huber; 2000. Sparshott M. Früh- und Neugeborene pflegen. Stress- und schmerzreduzierende und entwicklungsfördernde Pflege. Huber; 2000.
28.
Zurück zum Zitat Wohlmannstetter M. Überpflege – gibt es das auch? Med Klin – Intensiv Notfallmedizin. 2019;114:202–6.CrossRef Wohlmannstetter M. Überpflege – gibt es das auch? Med Klin – Intensiv Notfallmedizin. 2019;114:202–6.CrossRef
30.
Zurück zum Zitat Muresanu D. Neurotrophic factors. 2003. Muresanu D. Neurotrophic factors. 2003.
31.
Zurück zum Zitat Brazinova A, Majdan M, Leitgeb J, Trimmel H, Mauritz W. Care AWG on I of ET. Factors that may improve outcomes of early traumatic brain injury care: prospective multicenter study in Austria. Scand J Trauma Resusc Emerg Med. 2015;23:53–11.PubMedPubMedCentralCrossRef Brazinova A, Majdan M, Leitgeb J, Trimmel H, Mauritz W. Care AWG on I of ET. Factors that may improve outcomes of early traumatic brain injury care: prospective multicenter study in Austria. Scand J Trauma Resusc Emerg Med. 2015;23:53–11.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Geeraerts T, Velly L, Bouzat P, et al. Management of severe traumatic brain injury (first 24 hours). Crit Care. 2018;37:171–86. Geeraerts T, Velly L, Bouzat P, et al. Management of severe traumatic brain injury (first 24 hours). Crit Care. 2018;37:171–86.
33.
Zurück zum Zitat Gravesteijn BY, Sewalt CA, Lingsma HF, et al. Prehospital Management of Traumatic Brain Injury across Europe: A CENTER-TBI Study. Prehop Emerg Care. 2021;25:629–43.CrossRef Gravesteijn BY, Sewalt CA, Lingsma HF, et al. Prehospital Management of Traumatic Brain Injury across Europe: A CENTER-TBI Study. Prehop Emerg Care. 2021;25:629–43.CrossRef
34.
Zurück zum Zitat Margulies S, Hicks R. Leaders CT for TBIW. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma. 2009;26:925–39.PubMedPubMedCentralCrossRef Margulies S, Hicks R. Leaders CT for TBIW. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma. 2009;26:925–39.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Bergold PJ. Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol. 2016;275:367–80.PubMedCrossRef Bergold PJ. Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol. 2016;275:367–80.PubMedCrossRef
36.
Zurück zum Zitat Sayed IE, Zaki A, Abdelmonem S, et al. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev. 2016;41:427–38.PubMedCrossRef Sayed IE, Zaki A, Abdelmonem S, et al. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev. 2016;41:427–38.PubMedCrossRef
37.
Zurück zum Zitat Li M, Huo X, Jiang Z, et al. Effect of drug therapy on nerve repair of moderate-severe traumatic brain injury: A network meta-analysis. Front Pharmacol. 2022;13:1021653.PubMedPubMedCentralCrossRef Li M, Huo X, Jiang Z, et al. Effect of drug therapy on nerve repair of moderate-severe traumatic brain injury: A network meta-analysis. Front Pharmacol. 2022;13:1021653.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Marshall S, Ferri C, Harnett A, et al. Attention, Concentration, and Information Processing Post Acquired Brain Injury. Evidence-based Rev Moderate To Severe Acquir Brain Inj. 2022;. www.ERABI.ca. Marshall S, Ferri C, Harnett A, et al. Attention, Concentration, and Information Processing Post Acquired Brain Injury. Evidence-based Rev Moderate To Severe Acquir Brain Inj. 2022;. www.​ERABI.​ca.
40.
Zurück zum Zitat Herzer G, Mirth C, Trimmel H, et al. Analgosedation of adult patients with elevated intracranial pressure. Wien Klin Wochenschr. 2018;130:45–53.PubMedCrossRef Herzer G, Mirth C, Trimmel H, et al. Analgosedation of adult patients with elevated intracranial pressure. Wien Klin Wochenschr. 2018;130:45–53.PubMedCrossRef
41.
Zurück zum Zitat Godoy DA, Badenes R, Pelosi P, Robba C. Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”. Crit Care. 2021;25:19.PubMedPubMedCentralCrossRef Godoy DA, Badenes R, Pelosi P, Robba C. Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”. Crit Care. 2021;25:19.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Pfenninger E, Himmelseher S. Neuroprotektion durch Ketamin auf zellulärer Ebene. Anaesthesist. 1997;46:S47–S54.PubMedCrossRef Pfenninger E, Himmelseher S. Neuroprotektion durch Ketamin auf zellulärer Ebene. Anaesthesist. 1997;46:S47–S54.PubMedCrossRef
43.
Zurück zum Zitat Carrillo LR, Garcia KA, Yalcin N, Shah M. Ketamine and its emergence in the field of neurology. Cureus. 2022;14:e27389. Carrillo LR, Garcia KA, Yalcin N, Shah M. Ketamine and its emergence in the field of neurology. Cureus. 2022;14:e27389.
44.
Zurück zum Zitat Telles JPM, Welling LC, Figueiredo EG, et al. Cortical spreading depolarization and ketamine: a short systematic review. Neurophysiol Clinique. 2021;51:145–51.CrossRef Telles JPM, Welling LC, Figueiredo EG, et al. Cortical spreading depolarization and ketamine: a short systematic review. Neurophysiol Clinique. 2021;51:145–51.CrossRef
45.
Zurück zum Zitat Tang Y, Liu Y, Hua J, et al. Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK/mTOR-dependent TFEB nuclear translocation. Exp Neurol. 2023;366:114436.PubMedCrossRef Tang Y, Liu Y, Hua J, et al. Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK/mTOR-dependent TFEB nuclear translocation. Exp Neurol. 2023;366:114436.PubMedCrossRef
46.
Zurück zum Zitat Carlson AP, Abbas M, Shuttleworth CW, et al. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2019;130:1513–9.PubMedCrossRef Carlson AP, Abbas M, Shuttleworth CW, et al. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2019;130:1513–9.PubMedCrossRef
47.
Zurück zum Zitat Laws JC, Vance EH, Bonfield CM, et al. Acute Effects of Ketamine on Intracranial Pressure in Children With Severe Traumatic Brain Injury. Crit Care Med. 2023;51:563–72.PubMedPubMedCentralCrossRef Laws JC, Vance EH, Bonfield CM, et al. Acute Effects of Ketamine on Intracranial Pressure in Children With Severe Traumatic Brain Injury. Crit Care Med. 2023;51:563–72.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Mazandi VM, Lang S‑S, Zhang B, et al. Co-administration of Ketamine in Pediatric Patients with Neurologic Conditions at Risk for Intracranial Hypertension. Neurocrit Care. 2023;38:242–53.PubMedCrossRef Mazandi VM, Lang S‑S, Zhang B, et al. Co-administration of Ketamine in Pediatric Patients with Neurologic Conditions at Risk for Intracranial Hypertension. Neurocrit Care. 2023;38:242–53.PubMedCrossRef
49.
Zurück zum Zitat Ossola B, Schendzielorz N, Männistö PT, et al. Corrigendum to “Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia” [Neuropharmacology 61. Neuropharmacology. 2011;62(2012):1162–582. Ossola B, Schendzielorz N, Männistö PT, et al. Corrigendum to “Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia” [Neuropharmacology 61. Neuropharmacology. 2011;62(2012):1162–582.
50.
Zurück zum Zitat Ossola B, Schendzielorz N, Männistö PT, et al. Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology. 2011;61:574–82.PubMedPubMedCentralCrossRef Ossola B, Schendzielorz N, Männistö PT, et al. Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology. 2011;61:574–82.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Joseph T Giacino, John Whyte, Emilia Barilla et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. New Engl J Medicine. 2012;366:819–26.CrossRef Joseph T Giacino, John Whyte, Emilia Barilla et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. New Engl J Medicine. 2012;366:819–26.CrossRef
52.
Zurück zum Zitat Katlowitz K, Gopinath S, Navarro JC, Robertson C. HMG-coA Reductase inhibitors for traumatic brain injury. Neurotherapeutics. 2023; 1–8. Katlowitz K, Gopinath S, Navarro JC, Robertson C. HMG-coA Reductase inhibitors for traumatic brain injury. Neurotherapeutics. 2023; 1–8.
53.
Zurück zum Zitat Susanto M, Siahaan AMP, Aryanti C, et al. The neuroprotective effect of statin in traumatic brain injury: A systematic review. World Neurosurg. 2023;X(19):100211.CrossRef Susanto M, Siahaan AMP, Aryanti C, et al. The neuroprotective effect of statin in traumatic brain injury: A systematic review. World Neurosurg. 2023;X(19):100211.CrossRef
54.
Zurück zum Zitat Sultan W, Sapkota A, Went TR, et al. Statins’ Effect on Cognitive Outcome After Traumatic Brain Injury. Cureus. 2021;13:e16953.PubMedPubMedCentral Sultan W, Sapkota A, Went TR, et al. Statins’ Effect on Cognitive Outcome After Traumatic Brain Injury. Cureus. 2021;13:e16953.PubMedPubMedCentral
55.
Zurück zum Zitat Cho H‑J, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009;31:171.PubMedCrossRef Cho H‑J, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009;31:171.PubMedCrossRef
57.
Zurück zum Zitat Secades JJ Citicoline: pharmacological and clinical review, 2016 update. RevNeurol. 2016;63:S1–S73. Secades JJ Citicoline: pharmacological and clinical review, 2016 update. RevNeurol. 2016;63:S1–S73.
58.
Zurück zum Zitat Zafonte RD, Bagiella E, Hesdorffer DC, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308:1993–2000.PubMedCrossRef Zafonte RD, Bagiella E, Hesdorffer DC, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308:1993–2000.PubMedCrossRef
59.
Zurück zum Zitat Secades JJ, Trimmel H, Salazar B, González JA. Citicoline for the management of patients with traumatic brain injury in the acute phase: a systematic review and meta-analysis. Life. 2023; 369–84. Secades JJ, Trimmel H, Salazar B, González JA. Citicoline for the management of patients with traumatic brain injury in the acute phase: a systematic review and meta-analysis. Life. 2023; 369–84.
60.
Zurück zum Zitat Alvarez XA, Sampedro C, García-Fantini M, et al. Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm. 2008;115:683–92. Vienna, Austria : 1996.PubMedCrossRef Alvarez XA, Sampedro C, García-Fantini M, et al. Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury. J Neural Transm. 2008;115:683–92. Vienna, Austria : 1996.PubMedCrossRef
61.
Zurück zum Zitat Iznak AF, Iznak EV, Zavadenko NN, Guzilova LS. Neurophysiological indices of CNS plasticity in the course of treatment of head trauma in adolescents. Hum Physiol. 2008;34:672–7.CrossRef Iznak AF, Iznak EV, Zavadenko NN, Guzilova LS. Neurophysiological indices of CNS plasticity in the course of treatment of head trauma in adolescents. Hum Physiol. 2008;34:672–7.CrossRef
62.
Zurück zum Zitat Alvarez XA, Sampedro C, Hernández A, et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol. 2003;18:271–8.PubMedCrossRef Alvarez XA, Sampedro C, Hernández A, et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol. 2003;18:271–8.PubMedCrossRef
63.
Zurück zum Zitat Zhang Y, Chopp M, Lu M, et al. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabil Neural Repair. 2019;33:15–26.PubMedCrossRef Zhang Y, Chopp M, Lu M, et al. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabil Neural Repair. 2019;33:15–26.PubMedCrossRef
64.
Zurück zum Zitat Fiani B, Covarrubias C, Nikolaidis D, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurol Sci. 2021;42:1345–53.PubMedCrossRef Fiani B, Covarrubias C, Nikolaidis D, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurol Sci. 2021;42:1345–53.PubMedCrossRef
65.
Zurück zum Zitat Yang C, Qi Y, Sun Z. The Role of Sonic Hedgehog Pathway in the Development of the Central Nervous System and Aging-Related Neurodegenerative Diseases. Front Mol Biosci. 2021;8:711710.PubMedPubMedCentralCrossRef Yang C, Qi Y, Sun Z. The Role of Sonic Hedgehog Pathway in the Development of the Central Nervous System and Aging-Related Neurodegenerative Diseases. Front Mol Biosci. 2021;8:711710.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Caplan IF, Maguire-Zeiss KA. Toll-like receptor 2 signaling and current approaches for therapeutic modulation in Synucleinopathies. Front Pharmacol. 2018;9:417.PubMedPubMedCentralCrossRef Caplan IF, Maguire-Zeiss KA. Toll-like receptor 2 signaling and current approaches for therapeutic modulation in Synucleinopathies. Front Pharmacol. 2018;9:417.PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Zhang C, Chopp M, Zhang L, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke: Cerebrolysin Enhances Neurogenesis. J Neurosci Res. 2010;88:3275–81.PubMedPubMedCentralCrossRef Zhang C, Chopp M, Zhang L, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke: Cerebrolysin Enhances Neurogenesis. J Neurosci Res. 2010;88:3275–81.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Zhang L, Chopp M, Szalad A, et al. Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. Stroke. 2013;44:1965–72.PubMedCrossRef Zhang L, Chopp M, Szalad A, et al. Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. Stroke. 2013;44:1965–72.PubMedCrossRef
69.
Zurück zum Zitat Teng H, Li C, Zhang ZG, et al. Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. Publish im Druck. 2021. S. 359–66. Teng H, Li C, Zhang ZG, et al. Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. Publish im Druck. 2021. S. 359–66.
70.
Zurück zum Zitat Wong GKC, Zhu XL, Poon WS. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir Suppl. 2005;95:59–60.PubMedCrossRef Wong GKC, Zhu XL, Poon WS. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochir Suppl. 2005;95:59–60.PubMedCrossRef
71.
Zurück zum Zitat Poon W, Matula C, von Wild K, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I–a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41:281–93.PubMedCrossRef Poon W, Matula C, von Wild K, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I–a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41:281–93.PubMedCrossRef
72.
Zurück zum Zitat Muresanu DF, Florian S, Vos PE, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020;41:1171–81.PubMedCrossRef Muresanu DF, Florian S, Vos PE, et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020;41:1171–81.PubMedCrossRef
73.
Zurück zum Zitat Vester JC, Buzoianu AD, Lee TMC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021; 1–11. Vester JC, Buzoianu AD, Lee TMC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021; 1–11.
74.
Zurück zum Zitat Jarosz K, Kojder K, Jurczak A, et al. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. Brain Sci. 2023;13:507.PubMedPubMedCentralCrossRef Jarosz K, Kojder K, Jurczak A, et al. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. Brain Sci. 2023;13:507.PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Trimmel H, Majdan M, Brazinova A, et al. Citicoline in severe traumatic brain injury: indications for improved outcome : A retrospective matched pair analysis from 14 Austrian trauma centers. Wien Klin Wochenschrift. 2018;130:37–44.CrossRef Trimmel H, Majdan M, Brazinova A, et al. Citicoline in severe traumatic brain injury: indications for improved outcome : A retrospective matched pair analysis from 14 Austrian trauma centers. Wien Klin Wochenschrift. 2018;130:37–44.CrossRef
76.
Zurück zum Zitat Birle C, Slavoaca D, Stan AD, et al. The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury. J Med Life. 2020;13:283–8.PubMedPubMedCentralCrossRef Birle C, Slavoaca D, Stan AD, et al. The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury. J Med Life. 2020;13:283–8.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Varadaraju DN, Ananthakishan A. Effect of cerebroprotein hydrolysate with citicoline versus citicoline alone in the initial management of head injury and its clinical outcome a prospective randomised comparative study. J Évid Based Med Heal. 2017;4:2835–7. Varadaraju DN, Ananthakishan A. Effect of cerebroprotein hydrolysate with citicoline versus citicoline alone in the initial management of head injury and its clinical outcome a prospective randomised comparative study. J Évid Based Med Heal. 2017;4:2835–7.
79.
Zurück zum Zitat Muresanu DF, Ciurea AV, Stan H, et al. A retrospective, multi-center cohort study evaluating the severity–related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. Cns Neurol Disord Drug Targets. 2015;14:587–99.PubMedCrossRef Muresanu DF, Ciurea AV, Stan H, et al. A retrospective, multi-center cohort study evaluating the severity–related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. Cns Neurol Disord Drug Targets. 2015;14:587–99.PubMedCrossRef
80.
Zurück zum Zitat Ghaffarpasand F, Torabi S, Pakzad F, et al. Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsych Dis Treat. 2018;15:127–35.CrossRef Ghaffarpasand F, Torabi S, Pakzad F, et al. Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsych Dis Treat. 2018;15:127–35.CrossRef
81.
Zurück zum Zitat Trimmel H, Herzer G, Grgac I, et al. A novel pharmacological treatment concept for neuroprotection in severe traumatic brain injury–Two case reports. Clin Case Rep. 2022;10:e6626.PubMedPubMedCentralCrossRef Trimmel H, Herzer G, Grgac I, et al. A novel pharmacological treatment concept for neuroprotection in severe traumatic brain injury–Two case reports. Clin Case Rep. 2022;10:e6626.PubMedPubMedCentralCrossRef
Metadaten
Titel
Neuroprotektive und -regenerative Medikation nach schwerem Schädel-Hirn-Trauma
Sinnvolle Ergänzung der Intensivbehandlung?
verfasst von
Prim. Univ.-Prof. Dr. Helmut Trimmel
Ivan Grgac
Günther Herzer
Christian Matula
Publikationsdatum
07.11.2024
Verlag
Springer Vienna
Erschienen in
Anästhesie Nachrichten / Ausgabe 4/2024
Print ISSN: 2617-2127
Elektronische ISSN: 2731-3972
DOI
https://doi.org/10.1007/s44179-024-00264-0